Letter from GlaxoWellcome to CIPLA:
Importation of Duovir into Ghana


10th August, 2000

Cipla Ltd
Mumbai Central
Mumbai 400 008

FAO: Mr Amar Lulla, Director,

Dear Sirs,

Re: Lamivudine/Zidovudine combinations

It has come to our attention that you have imported your product Duovir, which contains lamivudine and zidovudine, into Ghana.

Glaxo Group Limited has exclusive rights under the following patents that cover lamivudine and zidovudine formulations in Ghana: AP11, AP136, AP182, AP300.

Importation of Duovir into Ghana by Cipla or any of its affiliates represents an infringement of our Company's exclusive patent rights. We understand that, to date, imports of Duovir into Ghana have been of limited scope and have been characterised as a "donation". We therefore do not intend to seek immediate redress. However, we reserve the right to enforce our patent rights against any further acts of infringement.

Yours faithfully,

G G Brereton
Head of Patents
Global Intellectual Property Department

| CPT Health Care Page | CPT Country Dispute page | CPT Africa page |